Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-186

Thanks @dungdang
A much easier read than today’s Top-line announcement for non-scientists like me. Still digesting it.

Looking beyond today’s bloodbath, on page 4 of Investor Presentation:
“This mechanism of increased treatment effect at higher levels of inflammatory disease burden is also consistent with the planned use of DMX-200 for the treatment of Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19 where high concentration of MCP-1 in lung fluid is correlated with poor patient outcomes and where DMX-200 may have the maximum effect.” Bring it on. Protocols are finished! Just waiting on other people for website REMAP-CAP to be done.